| Kathryn Mary Topalis, | |
|
797 S Fair Oaks Ave, Pasadena, CA 91105-2617 | |
| (626) 795-2244 | |
| (626) 795-5378 |
| Full Name | Kathryn Mary Topalis |
|---|---|
| Gender | Female |
| Speciality | Family Medicine |
| Location | 797 S Fair Oaks Ave, Pasadena, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205455482 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | A186641 (California) | Primary |
| Entity Name | Healthcare Partners Affiliates Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659312593 PECOS PAC ID: 7315842002 Enrollment ID: O20031204001258 |
News Archive
Individualized climate control for burns victims in hospitals might not only improve comfort for such patients, but improve working conditions for those taking care of them.
Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011, in Chicago. The abstracts provide additional data that demonstrate the safety and routes of administration of CEM-101, a new generation macrolide.
Every hour, an enormous quantity and variety of manmade chemicals, having reached the end of their useful lifespan, flood into wastewater treatment plants. These large-scale processing facilities, however, are designed only to remove nutrients, turbidity and oxygen-depleting human waste, and not the multitude of chemicals put to residential, institutional, commercial and industrial use.
A study by Susan Steck of the Arnold School of Public Health finds that a high intake of flavonoids, a group of compounds found in plants, may lower the risk for highly aggressive prostate cancer.
OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kathryn Mary Topalis, 21 Winterset Ln, Simsbury, CT 06070-1720 Ph: (860) 888-2728 | Kathryn Mary Topalis, 797 S Fair Oaks Ave, Pasadena, CA 91105-2617 Ph: (626) 795-2244 |
News Archive
Individualized climate control for burns victims in hospitals might not only improve comfort for such patients, but improve working conditions for those taking care of them.
Cempra Pharmaceuticals today announced abstracts to be presented on its fourth generation macrolide and novel fluoroketolide antibiotic, solithromycin (CEM-101), at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 17 to 20, 2011, in Chicago. The abstracts provide additional data that demonstrate the safety and routes of administration of CEM-101, a new generation macrolide.
Every hour, an enormous quantity and variety of manmade chemicals, having reached the end of their useful lifespan, flood into wastewater treatment plants. These large-scale processing facilities, however, are designed only to remove nutrients, turbidity and oxygen-depleting human waste, and not the multitude of chemicals put to residential, institutional, commercial and industrial use.
A study by Susan Steck of the Arnold School of Public Health finds that a high intake of flavonoids, a group of compounds found in plants, may lower the risk for highly aggressive prostate cancer.
OptiNose Inc. announces the filing of an Investigational New Drug (IND) with the U.S. Food and Drug Administration (FDA) in December, 2011. The FDA has completed its review and has notified OptiNose that the studies under this IND may proceed. The Company will initiate Phase III trials in adults with acute migraine with or without aura utilizing its novel intranasal technology.
› Verified 5 days ago
Dr. Matthew John Sexter, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1845 N Fair Oaks Ave # G-151, Pasadena, CA 91103 Phone: 562-867-7999 | |
Dr. Cindy Justo Uypitching, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 10 Congress St, Ste 208, Pasadena, CA 91105 Phone: 626-795-4210 Fax: 626-795-0740 | |
Dr. Arthur Mark Ayvazian, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 10 Congress St Ste 208, Pasadena, CA 91105 Phone: 626-792-2166 Fax: 626-795-0740 | |
Dr. John Y. F. Tsai, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1239 Arden Road Mc1-8, Pasadena, CA 91125 Phone: 626-395-6393 | |
Dr. Lauren Wolchok, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 1845 N Fair Oaks Ave Ste G-151, Pasadena, CA 91103 Phone: 562-867-7999 | |
Dr. Tina I Harutunians, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 450 N Lake Ave, Pasadena, CA 91101 Phone: 626-405-6442 | |
Alina Ter-grigorian, NP Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1100 Valley View Ave, Pasadena, CA 91107 Phone: 626-316-3008 |